Evommune (EVMN) Total Current Liabilities (2024 - 2026)

Evommune (EVMN) has 3 years of Total Current Liabilities data on file, last reported at $10.6 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $10.6 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $10.6 million (changed N/A YoY), and the FY2025 annual result was $17.9 million, down 36.0% from the prior year.
• Total Current Liabilities fell to $10.6 million in Q1 2026 per EVMN's latest filing, from $17.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $28.0 million in Q4 2024 and troughed at $10.4 million in Q3 2025.
• A 3-year average of $16.7 million and a median of $14.3 million in 2025 frame the typical range for Total Current Liabilities.
• On a YoY basis, Total Current Liabilities climbed as much as 36.0% in 2025 and fell as far as 36.0% in 2025.
• A 3-year view of Total Current Liabilities shows it stood at $28.0 million in 2024, then plunged by 36.0% to $17.9 million in 2025, then tumbled by 40.8% to $10.6 million in 2026.
• Business Quant data shows EVMN's Total Current Liabilities at $10.6 million in Q1 2026, $17.9 million in Q4 2025, and $10.4 million in Q3 2025.